Overview

A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborator:
M.D. Anderson Cancer Center
Treatments:
Antibodies, Monoclonal
Nivolumab